**
In a remarkable response to a devastating Ebola outbreak, health authorities in the Democratic Republic of the Congo (DRC) have initiated a swift clinical trial aimed at evaluating two potential treatments. With the first patients enrolled just six weeks after the World Health Organization (WHO) declared the outbreak a public health emergency on 17 May, researchers are hopeful that these trials could significantly reduce mortality rates from the Bundibugyo strain of the virus.
Rapid Response to a Dire Situation
The outbreak, which has claimed 625 lives out of 1,792 confirmed cases as of 9 July, has left the residents of Ituri province in a state of distress. Many, like local mother Neema Haba, express their desperation: “Financially, we are being driven to the brink by this outbreak and nothing is going right.” Community members are grappling with the emotional and economic fallout, as the virus spreads amid a backdrop of fear and mistrust towards health authorities.
The ongoing crisis has relied heavily on traditional containment strategies, including case identification, isolation, and contact tracing. Yet, despite efforts to trace around 75% of known contacts, the response has been hampered by scepticism from the local populace and disruptions caused by civil unrest. Frontline health workers have taken to protesting for overdue wages, further complicating the already challenging landscape of the outbreak response.
Innovative Treatments Under Trial
The ambitious Partners treatment trial has commenced with the administration of two drugs: remdesivir, an antiviral developed by Gilead Sciences, and MBP134, a monoclonal antibody created by Mapp Biopharmaceutical. Participants in the trial will receive either of the drugs, a combination of both, or standard supportive care, with the aim of determining their effectiveness against the Bundibugyo strain.
Prof. Laurens Liesenborghs from the Institute of Tropical Medicine in Antwerp, who is overseeing the trial, stated: “These two drugs have shown great efficacy in animal models. Our objective is to ascertain if they can lower mortality rates in human patients.” Notably, while Bundibugyo typically has a lower death rate than the more notorious Zaire strain, it still claims approximately one in three lives.
The Role of the Global Community
The WHO has reported that sufficient supplies of both remdesivir and MBP134 have been secured for 1,200 patients, thanks to donations from Gilead and the US government. Prof. Amanda Rojek from the University of Oxford expressed her pride in the rapid establishment of the trial, contrasting it with the extensive delays seen during the West African outbreak from 2014-2016. “We’ve managed to achieve this in six weeks since the outbreak was first announced,” she remarked, highlighting the crucial role of local scientific leadership.
The trial is designed to be flexible, allowing for the introduction of additional treatments as they become available. Importantly, it also includes participants of all ages, including pregnant and breastfeeding women, who are often excluded from such medical studies. This inclusive approach underscores the high stakes involved in providing potential life-saving treatments to those in dire need.
Why it Matters
The swift initiation of these clinical trials marks a significant turning point in the fight against Ebola in the DRC. With mortality rates soaring and the community in turmoil, the success of these treatments could not only save countless lives but also restore trust in health authorities. By providing effective care, the trials may serve as a beacon of hope, demonstrating the possibility of overcoming such a formidable health crisis. The world watches closely, as the outcomes of these trials could have far-reaching implications for future Ebola outbreaks and global health responses.
